Recombinant Human Apolipoprotein A I / APOA1 Protein

Name: Recombinant Human Apolipoprotein A I / APOA1 Protein
Brand: Beta LifeScience
SKU: BLA-0093P
Availability: InStock

Collections: All products, Buy cytokines, chemokines, and growth factors for research online, High-quality recombinant proteins, Other cytokines

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Host Species	Human
Accession	P02647
Synonym	Apo-AI ApoA I ApoA-I APOA1 APOA1_HUMAN Apolipoprotein A-I(1-242) Apolipoprotein A1 Apolipoprotein AI Apolipoprotein of high density lipoprotein ApolipoproteinAI Brp14 high density lipoprotein uptake Ltw1 Lvtw1 MGC117399 Sep1 Sep2
Description	Recombinant Human Apolipoprotein A I / APOA1 Proteinwas expressed in HEK293. It is a Full length protein
Source	HEK293
AA Sequence	DEPPQS PWDRVKDLAT VYVDVLKDSG RDYVSQFEGS ALGKQLNLKL LDNWDSVTST FSKLREQLGP VTQEFWDNLE KETEGLRQEM SKDLEEVKAK VQPYLDDFQK KWQEEMELYR QKVEPLRAEL QEGARQKLHE LQEKLSPLGE EMRDRARAHV DALRTHLAPY SDELRQRLAA RLEALKENGG ARLAEYHAKA TEHLSTLSEK AKPALEDLRQ GLLPVLESFK VSFLSALEEY TKKLNTQ
Molecular Weight	29 kDa including tags
Purity	Greater than 95% SDS-PAGE
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity	Immobilized Human Apolipoprotein A I at 10 µg/mL (100 µl/well) can bind biotinylated Human SCARB1. The EC50 of biotinylated human SCARB1 is 10-100 ng/mL.
Formulation	Lyophilised
Stability	The recombinant protein samples are stable for up to 12 months at -80°C
Reconstitution	See related COA
Unit Definition	For Research Use Only
Storage Buffer	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

Target Details

Target Function	Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
Subcellular Location	Secreted.
Protein Families	Apolipoprotein A1/A4/E family
Database References	HGNC: 600 OMIM: 105200 KEGG: hsa:335 STRING: 9606.ENSP00000236850 UniGene: PMID: 29915952 This study explores how the high-density lipoproteins lipid composition influences amyloid deposition by apoA-I and related proteins. PMID: 27768903 Site-specific, covalent modifications of apoA-I (lysines or arginines) led to altered protein structure, reduced lipid binding capability and a reduced ability to catalyze cholesterol efflux from macrophages, partly in a modification-specific manner. PMID: 29802959 assessing the quality of ApoA1 and, in turn, that of HDL in circulating blood can serve as an early diagnostic tool for cardiovascular diseases (CVDs). In this study, we developed monoclonal antibodies (mAbs) specific to modified ApoA1 with its tyrosine residue at the 166th position nitrated to 3-nitrotyrosine PMID: 30132720 Vitreous levels of APOA1 and RBP4 in human rhegmatogenous retinal detachment associated with choroidal detachment reflects the severity of disease. PMID: 29618920 The objective of this study was to evaluate whether apolipoprotein gene polymorphisms confer susceptibility to osteonecrosis of the femoral head. PMID: 30119683 Case Report: recurrence of non-familial hereditary apolipoprotein A-I amyloidosis in Japanese transplant recipient with two novel APOA1 mutations. PMID: 29968409 TNFalpha differently regulated the levels of PPARalpha, LXRalpha, and LXRbeta binding to the apoA-I gene promoter in THP-1 cells. Obtained results suggest a novel tissue-specific mechanism of the TNFalpha-mediated regulation of apoA-I gene in monocytes and macrophages and show that endogenous ApoA-I might be positively regulated in macrophage during inflammation. PMID: 29442267 An increased apo B/apo A1 ratio was independently associated with all-cause mortality and cardiovascular events in peritoneal dialysis patients. PMID: 29776362 he present study reveals that there may be a racial/ethnic- and/or gender-specific association between the APOA1 rs964184 SNP and serum lipid parameters in our study populations PMID: 29747660 In this study the APOA1 (rs670) gene showed important effects on body weight, adiposity, LDL-cholesterol levels and insulin resistance after 12weeks of the dietary intervention PMID: 29859275 Residues 26-43 of one APOA1 in the smaller particle form a hinge on the disc edge, which displaces the C-terminal domain of the other APOA1 to the phospholipid surface PMID: 29712830 H1 receptor signaling is a novel pathway of apo A1 gene expression PMID: 29378195 genetic polymorphisms of ApoA1 rs5070 A/G may play a role in the susceptibility to large artery atherosclerosis among male diabetic patients. PMID: 28238629 Single Nucleotide Polymorphism in APOA1 gene is associated with dyslipidemia. PMID: 29758034 rs670, rs2854116, and rs662799 single nucleotide polymorphisms of the APOA1-C3-A5 cluster are associated with ischemic stroke in the northern Chinese Han population. PMID: 28635360 Higher levels of TG, LPO (P<0.0001), nonHDL/HDL and ApoB/ApoA1 (P<0.001, 0.05, respectively), and lower levels of HDL-c, ApoA1, and PON1 (P<0.0001) were observed in T2DM subjects than in controls. PMID: 29626583 Data suggest that N(epsilon)-(carboxyethyl)lysine (CEL) modification of ApoA1 is up-regulated in serum from patients with Alzheimer's disease (AD); CEL-ApoA1 is a kind of advanced glycation end product; this leads to up-regulation of anti-CEL-ApoA1 IgM in early disease. Both CEL and anti-CEL IgM may serve as AD biomarkers. PMID: 29680706 The osteonecrosis of the femoral head patients had higher A/A genotype proportions on the apolipoprotein A1 gene 75bp, compared to the control group, while the G/A genotype frequency was lower in the affected patients. This suggests that the G/A mutation on Apo A1 promoter might be one of the predisposing factors for osteonecrosis of the femoral head. PMID: 28770971 Independent evidence indicated LpAI:A-II has a diameter 20% smaller than LpAI, consistent with a model having two apoA-I and one apoA-II PMID: 27526664 ApoA1 combined with 9alpha,11ss-PGF2 represents a useful composite biomarker of anaphylaxis, achieving superior diagnostic power over either factor alone. PMID: 28378321 Low-dose lipid-free apoA-I treatment in atherosclerotic mice preserves and restores collecting lymphatic vessels function by direct and indirect mechanisms. PMID: 28939717 APOA1 gene may be associated with low HDL-cholesterol disease in the pastoral area of northwest China. PMID: 28969676 Our results strongly suggest that plasma concentrations of EPA and DHA influence aspirin effects on lipid mediators of CVD event risk where their concentrations are most beneficial when moderate, not high or low. These effects on HDL-C cholesterol and apoA-I exchange are novel. PMID: 29031392 A multidisciplinary approach, including circular dichroism, dynamic light scattering, spectrofluorometric and atomic force microscopy analyses, monitored the effect of target cells on the conformation and fibrillogenic pathway of the two AApoAI amyloidogenic variants AApoAI(L75P) and AApoAI(L174S). Specific cell milieus selectively affect conformation, aggregation propensity and fibrillogenesis of these variants. PMID: 29174954 we demonstrated a 21.6% decrease in serum ApoA-I in FA patients compared with non-affected controls PMID: 29447225 Smaller apolipoprotein(a) isoform size and increased lipoprotein(a) concentration are independent and causal risk factors for coronary heart disease. PMID: 28408323 In conclusion, decreasing levels of apolipoproteins B and A1 were associated with increased risk of venous thrombosis. PMID: 28540474 Serum ApoA-I level was negatively correlated with the formation of vocal fold polyps, suggesting ApoA-I may reduce the risk of vocal fold polyps. PMID: 27816355 data indicate that low apoA1 levels are an independent predictor of the poor clinical outcomes in invasive ductal carcinoma patients. PMID: 28595037 Data suggest that Apolipoprotein A1 (ApoA-1) might be a promising therapeutic target to reduce recurrence and metastasis for hepatocellular carcinoma (HCC) patients after resection. PMID: 27683106 The generated structures provide evidence for the discoidal, antiparallel arrangement of apoA-I in nascent HDL, and propose two preferred conformations of the flexible N-termini PMID: 28754383 identified that apolipoprotein-A1 and haptoglobin had significant predictive values for the prediction of recovery at 12 weeks in DILI, enabling the construction of a new prognostic panel, the DILI-ActiTest, which needs to be independently validated PMID: 29287080 ApoA1 is associated with neurite outgrowth after mechanical injury by mediating polymerisation of actin and restricting inflammatory responses after injury which are deleterious to healing. PMID: 27100352 A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I PMID: 29030428 Lower ApoA1 improves the risk prediction of new type 2 diabetes PMID: 28502492 Following ETC-216 administration to normal human volunteers, an initial dose-dependent HDL-C elevation was observed. Thereafter, subjects transiently acquired a lipoprotein profile similar to that of AIM carriers, including reduced HDL-C and mild hypertriglyceridemia. PMID: 27155060 The different anti-inflammatory mechanisms of the ApoA-I cysteine mutants might be associated with the regulation of ATF3 level. PMID: 28093456 Anti-apoA-1 IgG are independent predictors of nonfatal incident coronary artery disease in the general population. The strength of this association is dependent on a functional polymorphism of the CD14 receptor gene, a finding suggesting a gene-autoantibody interaction for the development of CAD. PMID: 29074586 In vitro proteolysis of the apoA-I-Cy5.5 probe by a variety of proteases including serine, cysteine, and metalloproteases resulted in an up to 11-fold increase in fluorescence, allowing for quantification of apolipoprotein A-I proteolytic degradation. PMID: 28167355 Using atomic force microscopy, detail the ring-shaped coarse structure, and the three detailed structures of apoA-I directly derived from spherical HDL through NP-40-induced lipid depletion. PMID: 28279834 These data suggest that high doses of insulin downregulate apoA-I gene expression in HepG2 cells through redistribution of FOXO1/LXRbeta complex, FOXA2, and LXRalpha on hepatic enhancer of apoA-I gene. PMID: 27404023 Our findings suggest that serum ApoA-I level should be evaluated as a predictor of survival in patients with esophageal squamous cell carcinoma PMID: 27444612 Inflammatory markers modify the risk of recurrent coronary events associated with apolipoprotein A-I in postinfarction patients PMID: 28391888 Serum Apo-A1 was significantly lower in term SGA newborns compared to control term newborns. PMID: 28304324 This study showed that the predictive value of apolipoprotein B/A-I ratio for coronary artery calcification may differ according to kidney function. PMID: 28957410 Findings suggest that the ABCG1-mediated efflux of cholesterol, but not of 7-ketocholesterol, shows specificity for structural domains of apoA-I bound to reconstituted HDL. Although the mid region alone of apoA-I associated to rHDL can promote ABCG1-mediated cholesterol efflux, deletion of carboxyl-terminal region 185-243 from full-length apoA-I diminishes ABCG1-mediated cholesterol efflux. PMID: 23826352 Low APOA1 expression is associated with coronary artery disease severity. PMID: 28038449 Data suggest that activation of SR-BI by APOAI down-regulates sphingosine 1-phosphate/S1PR2-mediated inflammation in vascular endothelial cells by activating the PI3K/Akt signaling pathway; oxidized-LDL does the opposite. (APOA1 = apolipoprotein A-I; SR-BI/SCARB1 = scavenger receptor class B type I; S1PR2 = sphingosine 1-phosphate receptor 2; PI3K = phosphatidylinositol 3-kinase; Akt = proto-oncogene c-akt) PMID: 28181168 The minor alleles of rs662799 (APOA5) and rs5072 (APOA1) modulate TG levels in Mexican children PMID: 27171122

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.